AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aprea Therapeutics Reports Q3 FY25 Financial Results and Clinical Updates
ByAinvest
Wednesday, Nov 12, 2025 8:40 am ET1min read
• Aprea Therapeutics reports Q3 2025 financial results • APR-1051 WEE1 kinase inhibitor shows 75% stable disease in Phase 1 trial • ATRN-119 ATR kinase inhibitor reaches RP2D of 1,100 mg in dose-escalation study • Posters on APR-1051 and ATRN-119 featured at AACR-NCI-EORTC conference • Stable disease seen in 3 out of 4 patients at Dose Level 6 of APR-1051 trial • Aprea Therapeutics focuses on exploiting cancer cell vulnerabilities in treatment development.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet